• Efficacy in facial global photodamage [ Time Frame: 8 months ] [ Designated as safety issue: No ]
  

• 1-Facial fine lines, mottled pigmentation, tactile roughness, sallowness, erythema, telangiectasia 2-Histological effect of MAL+PDT in fibrosis and new collagen formation 3-Safety and tolerance [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  

It has been demonstrated that photodamage leads to wrinkles, mottled pigmentation, lentigines, telangiectasias, and textural changes, but more importantly, it can also lead to pre-cancerous conditions with the development of actinic keratosis (AK). The majority of photorejuvenation or photodamaged published studies have used 5-Amino-Levulinic acid (5-ALA) as a photosensitizer, and either a blue light or an Intense Pulsed Light source with a 70%-95% global facial skin improvement. The molecular mechanism of such improvement is unknown, but activation of a non-specific immune response in addition to increased fibrosis and new collagen formation, have both been suggested.

Methyl Aminolevulinate ( MAL) is another marketed photosensitizer mainly utilized in Europe. Lipophilicity, higher penetration depth and tumor selectivity has been advocated for MAL compared to 5-ALA. However, its effect in photodamaged skin has not been well documented.

The aim of the study is to determine the efficacy of MAL + Aktilite (PDT) in facial photodamage.

Study Type: Interventional

Study Design: Randomized, double-Blind, placebo-controlled trial. Official Title: A randomized, double-Blind, placebo-controlled trial of Methyl Aminolevulinate + Aktilite in patients with facial photodamage.

Inclusion Criteria:

• Female subjects older than 35 years of age and less than 75 years of age
• Subjects with a photodamage grade of 2 or 3 according to a modified Dover´s Global photodamage scale
• Subjects willing to participate according to protocol requirements.
• Patients with signed Informed Consent
• Patients with no exclusion criteria

Exclusion Criteria:

• Pregnant or nursing females.
• Subjects with suspected porphyria, Systemic or cutaneous erythematosus lupus, or any other photosensitizing disorder or drug induced photosensitization.
• Any active infectious skin disorder ( Herpes simplex, molluscum contagiosum, facial warts )
• Subjects with less than 6 months of previous rejuvenation interfering treatments
• Subjects requiring concurrent treatment that would interfere with study objectives and/or assessments.